SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that it will unveil a commercially available system for high-parameter tissue imaging on Tuesday, October 24, 2017, via a global livestream video.
This new imaging system significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to results from standard fluorescent immunohistochemistry methods. With the potential to revolutionize disease research and change the way diseases are treated and ultimately cured in the future, this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.
We invite our colleagues from across the life science industry to join us online at fluidigm.com/futureofimaging for a unique view into the potential of this new technology on Tuesday, October 24, 2017, at 7:00 a.m. PT (10:00 a.m. ET).
Come see the future of imaging
The program will include live presentations by Chris Linthwaite, President and CEO of Fluidigm, and leading scientists who will share their insights and experiences with this revolutionary new approach to tissue imaging.
President and CEO
Bernd Bodenmiller, PhD
Institute of Molecular Life Sciences
University of Zurich
Matt Silver, PhD
Global Clinical Biomarkers and Companion Diagnostics
Akil Merchant, MD
Assistant Professor of Medicine
Keck School of Medicine
University of Southern California
“I am very excited to empower members of the global research community with this innovative new system and enable them to transform our understanding of life, leading to the development of better diagnostics and more effective therapies in the future,” said Linthwaite. “Join us for this exciting event on the 24th and hear firsthand about the next frontier in tissue imaging.”
View video message from Chris
The program will be available via livestream video from the InterContinental Toronto Centre, Toronto, Canada. A link to the webcast will not be active until 6:45 a.m. PT (9:45 a.m. ET) on October 24, 2017. A video replay of the live webcast will be available 120 minutes after the end of the meeting at fluidigm.com/futureofimaging and will be archived on fluidigm.com.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Senior Director, Marketing
650 737 4190
Source: Fluidigm Corporation